# JNCI: Journal of the National Cancer Institute

Source: https://onco.cc/journals/jnci/  
OnCo record `jnci` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JNCI began as the US National Cancer Institute's own journal and is now independent. It is strong on cancer epidemiology, screening, trial methodology and health disparities.

## Summary

Founded in 1940 as the NCI's journal and now published by Oxford University Press with an independent editorial board. Publishes epidemiology and risk-factor studies, screening and surveillance research, trial-methods and trial-participation analyses (Unger's 2019 review of barriers to trial enrolment in this corpus), and the annual US 'Report to the Nation' on cancer status. Hybrid access.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: JNCI; J Natl Cancer Inst; src-jnci
- Publisher: Oxford University Press
- Scope: cancer epidemiology
- Access: hybrid

## Notes

- Holds: Epidemiology, screening, health policy and trials. Access: Paywalled; some open access.

## Sources

- JNCI Cancer Spectrum (open access sister): https://academic.oup.com/jncics

## Connected records

- journals: [JNCI cancer spectrum](https://onco.cc/journals/jnci-cancer-spectrum/), [Journal of the National Cancer Institute. Monographs](https://onco.cc/journals/jnci-monographs/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- key papers: [A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients](https://onco.cc/key-papers/paper-montgomery-j-natl-cancer-inst/), [An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening](https://onco.cc/key-papers/paper-hu-j-natl-cancer-inst/), [Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report](https://onco.cc/key-papers/paper-johnson-j-natl-cancer-inst/), [Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial](https://onco.cc/key-papers/paper-lu-j-natl-cancer-inst/), [Colorectal cancer incidence patterns in the United States, 1974-2013](https://onco.cc/key-papers/paper-siegel-colorectal-incidence-birth-cohort-jnci-2017/), [Concordance of circulating tumour DNA and matched metastatic tissue biopsy in prostate cancer](https://onco.cc/key-papers/paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017/), [Effect of Aspirin on Cancer Incidence and Mortality in Older Adults](https://onco.cc/key-papers/paper-mcneil-j-natl-cancer-inst/), [Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India](https://onco.cc/key-papers/paper-shastri-j-natl-cancer-inst/), [Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial](https://onco.cc/key-papers/paper-hanai-j-natl-cancer-inst/), [Effects of St. John's wort on irinotecan metabolism](https://onco.cc/key-papers/paper-mathijssen-j-natl-cancer-inst/), [EORTC 24891: larynx preservation with induction chemotherapy in pyriform sinus (hypopharyngeal) cancer](https://onco.cc/key-papers/paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996/), [Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer](https://onco.cc/key-papers/paper-foulkes-brca1-basal-phenotype-jnci-2003/), [Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context](https://onco.cc/key-papers/paper-draisma-lead-time-overdiagnosis-psa-jnci-2009/), [Overdiagnosis in cancer](https://onco.cc/key-papers/paper-welch-j-natl-cancer-inst/), [PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/), [Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab](https://onco.cc/key-papers/paper-luca-gianni-j-natl-cancer-inst-2022/), [Prognostic significance of POLE proofreading mutations in endometrial cancer](https://onco.cc/key-papers/paper-church-pole-endometrial-jnci-2015/), [Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms](https://onco.cc/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/), [Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005](https://onco.cc/key-papers/paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009/), [Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing](https://onco.cc/key-papers/paper-shimelis-tnbc-risk-genes-jnci-2018/), [Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes](https://onco.cc/key-papers/paper-unger-trial-participation-barriers-jnci-2019/), [Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach](https://onco.cc/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/), [US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status](https://onco.cc/key-papers/paper-howlader-us-incidence-breast-subtypes-jnci-2014/), [Use of alternative medicine for cancer and its impact on survival](https://onco.cc/key-papers/paper-johnson-alternative-medicine-jnci-2018/), [Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2](https://onco.cc/key-papers/paper-barton-j-natl-cancer-inst/)
- people: [Carla van Gils](https://onco.cc/people/carla-van-gils/)

---
JSON: https://onco.cc/api/v1/entities/jnci.json